Last reviewed · How we verify

NCT06825754

The Value of Serum MicroRNA-21-5p and LncRNAgadd7 Expression Levels in Predicting the Severity and Prognosis of ARDS ( Acute Respiratory Distress Syndrome )

Completed Last updated 13 February 2025
What this trial tests

trial in Acute Respiratory Distress Syndrome in 110 participants. Completed in 10 January 2025.

Timeline
1 November 2023
Primary endpoint
30 November 2024
10 January 2025

Quick facts

Lead sponsorShao Yuekai
StatusCompleted
Study typeOBSERVATIONAL
Enrollment110
Start date1 November 2023
Primary completion30 November 2024
Estimated completion10 January 2025
Sites1 location across China

Conditions studied

Sponsor

Shao Yuekai

Who can join

18 and older, any sex, with Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

By measuring the expression levels of MicroRNA-21-5p (miR-21-5p) and LncRNAgadd7 in the peripheral blood of ARDS patients, the study aims to explore the correlation between these levels and the severity and prognosis of ARDS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Respiratory Distress Syndrome

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06825754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing